Currently, the best biomarkers used to detect early-stage AD are the pathological biomarkers Aβ and Tau, detected using PET-CT scanning or CSF detection (Lista et al., 2014; Jack et al., 2018). The gene discussed is MAPT; the disease is Alzheimer disease.